Aida Mohammadi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Aida Mohammadi has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Ali Nazeri Astaneh
University of Social Welfare and Rehabilitation Sciences, Tehran, Iran
1 shared publication - Alireza Mokhtari
Student Research Committee, Dental Faculty, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
1 shared publication - Arshia Khanjarani
Student Research Committee, Dental Faculty, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran;
1 shared publication - Aryan Jafari
Dental Materials Research Center, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
1 shared publication - Gita Sadighi
Psychosis Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran
1 shared publication - Hamoun Sabri
Department of Periodontics and Oral Medicine, University of Michigan School of Dentistry, Ann Arbor, USA
1 shared publication
Latest Publications
- Open Access
- 10 April 2024
- Published by Wiley in Neuropsychopharmacology Reports
- Vol. 44 (2) , 389-398
Co‐administration of probiotic and vitamin D significantly improves cognitive function in schizophrenic patients: A double‐blinded randomized controlled trial
Aim: Manipulation of the intestinal microbiome and supplying vitamin D can attenuate psychiatric symptoms in schizophrenic patients. The current study tried to evaluate the effects of probiotic/vitamin D supplementation on the cognitive function and disease severity of schizophrenic patients.Methods: In the present study, 70 patients (aged 18–65) with schizophrenia were recruited. Participants were randomly allocated to the placebo (n = 35) and intervention (probiotic supplements+400 IU vitamin D, n = 35) groups. Severity of disease and cognitive function (primary outcomes) were evaluated by Positive and Negative Syndrome Scale (PANSS) and Montreal Cognitive Assessment (MoCA) tests, respectively. Moreover, lipid profile, body mass index (BMI), gastrointestinal (GI) problems, serum C‐reactive protein (CRP), and erythrocyte sedimentation rate (ESR) were evaluated as secondary outcomes.Results: A total of 69 patients completed the study. The MoCA score was increased by 1.96 units in the probiotic‐containing supplement group compared to the placebo (p = 0.004). Also, the percentage of subjects with MoCA score ≥ 26 rose significantly in the intervention group (p = 0.031). Moreover, TC (p = 0.011), FBS (p = 0.009), and CRP (p < 0.001) significantly decreased in the supplement group compared to the placebo. Although the probiotic supplement reduced PANSS score by 2.82 units, the difference between the study groups was not statistically significant (p = 0.247).Conclusion: Co‐administration of probiotics and vitamin D has beneficial effects on the improvement of cognitive function in schizophrenic patients.
- 10 April 2024
- Published by Wiley in Neuropsychopharmacology Reports
- Vol. 44 (2) , 389-398
Open AccessCo‐administration of probiotic and vitamin D significantly improves cognitive function in schizophrenic patients: A double‐blinded randomized controlled trial
Aim: Manipulation of the intestinal microbiome and supplying vitamin D can attenuate psychiatric symptoms in schizophrenic patients. The current study tried to evaluate the effects of probiotic/vitamin D supplementation on the cognitive function and disease severity of schizophrenic patients.Methods: In the present study, 70 patients (aged 18–65) with schizophrenia were recruited. Participants were randomly allocated to the placebo (n = 35) and intervention (probiotic supplements+400 IU vitamin D, n = 35) groups. Severity of disease and cognitive function (primary outcomes) were evaluated by Positive and Negative Syndrome Scale (PANSS) and Montreal Cognitive Assessment (MoCA) tests, respectively. Moreover, lipid profile, body mass index (BMI), gastrointestinal (GI) problems, serum C‐reactive protein (CRP), and erythrocyte sedimentation rate (ESR) were evaluated as secondary outcomes.Results: A total of 69 patients completed the study. The MoCA score was increased by 1.96 units in the probiotic‐containing supplement group compared to the placebo (p = 0.004). Also, the percentage of subjects with MoCA score ≥ 26 rose significantly in the intervention group (p = 0.031). Moreover, TC (p = 0.011), FBS (p = 0.009), and CRP (p < 0.001) significantly decreased in the supplement group compared to the placebo. Although the probiotic supplement reduced PANSS score by 2.82 units, the difference between the study groups was not statistically significant (p = 0.247).Conclusion: Co‐administration of probiotics and vitamin D has beneficial effects on the improvement of cognitive function in schizophrenic patients.
- 1 March 2024
- Published by Bentham Science Publishers Ltd. in Current Reviews in Clinical and Experimental Pharmacology
- Vol. 19 (1) , 42-60
Effects of Drugs and Chemotherapeutic Agents on Dental Implant Osseointegration: A Narrative Review
Background: Dental implants have been one of the most popular treatments for rehabilitating individuals with single missing teeth or fully edentulous jaws since their introduction. As more implant patients are well-aged and take several medications due to various systemic conditions, clinicians should be mindful of possible drug implications on bone remodeling and osseointegration. Objective: The present study aims to study and review some desirable and some unwelcomed implications of medicine on osseointegration. Methods: A broad search for proper relevant studies were conducted in four databases, including Web of Science, Pubmed, Scopus, and Google Scholar. Results: Some commonly prescribed medicines such as nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, proton pump inhibitors (PPIs), selective serotonin reuptake inhibitors (SSRIs), anticoagulants, metformin, and chemotherapeutic agents may jeopardize osseointegration. On the contrary, some therapeutic agents such as anabolic, anti-catabolic, or dual anabolic and anti-catabolic agents may enhance osseointegration and increase the treatment’s success rate. Conclusion: Systemic medications that enhance osseointegration include mineralization promoters and bone resorption inhibitors. On the other hand, medications often given to the elderly with systemic problems might interfere with osseointegration, leading to implant failure. However, to validate the provided research, more human studies with a higher level of evidence are required.
- 1 March 2024
- Published by Bentham Science Publishers Ltd. in Current Reviews in Clinical and Experimental Pharmacology
- Vol. 19 (1) , 42-60
Effects of Drugs and Chemotherapeutic Agents on Dental Implant Osseointegration: A Narrative Review
Background: Dental implants have been one of the most popular treatments for rehabilitating individuals with single missing teeth or fully edentulous jaws since their introduction. As more implant patients are well-aged and take several medications due to various systemic conditions, clinicians should be mindful of possible drug implications on bone remodeling and osseointegration. Objective: The present study aims to study and review some desirable and some unwelcomed implications of medicine on osseointegration. Methods: A broad search for proper relevant studies were conducted in four databases, including Web of Science, Pubmed, Scopus, and Google Scholar. Results: Some commonly prescribed medicines such as nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, proton pump inhibitors (PPIs), selective serotonin reuptake inhibitors (SSRIs), anticoagulants, metformin, and chemotherapeutic agents may jeopardize osseointegration. On the contrary, some therapeutic agents such as anabolic, anti-catabolic, or dual anabolic and anti-catabolic agents may enhance osseointegration and increase the treatment’s success rate. Conclusion: Systemic medications that enhance osseointegration include mineralization promoters and bone resorption inhibitors. On the other hand, medications often given to the elderly with systemic problems might interfere with osseointegration, leading to implant failure. However, to validate the provided research, more human studies with a higher level of evidence are required.